

Beata Berent-Maoz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11538925/publications.pdf>

Version: 2024-02-01

21
papers

7,477
citations

516710

16
h-index

642732

23
g-index

23
all docs

23
docs citations

23
times ranked

13899
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. <i>Cell</i> , 2016, 165, 35-44.	28.9	2,437
2	Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. <i>New England Journal of Medicine</i> , 2016, 375, 819-829.	27.0	2,430
3	Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations. <i>Cancer Discovery</i> , 2017, 7, 188-201.	9.4	997
4	Causes, consequences, and reversal of immune system aging. <i>Journal of Clinical Investigation</i> , 2013, 123, 958-965.	8.2	570
5	Immunotherapy Resistance by Inflammation-Induced Dedifferentiation. <i>Cancer Discovery</i> , 2018, 8, 935-943.	9.4	130
6	Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. <i>Cancer Discovery</i> , 2020, 10, 1140-1157.	9.4	97
7	PAK4 inhibition improves PD-1 blockade immunotherapy. <i>Nature Cancer</i> , 2020, 1, 46-58.	13.2	85
8	A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab. <i>Clinical Cancer Research</i> , 2019, 25, 2096-2108.	7.0	69
9	Distinct Genetic Networks Orchestrate the Emergence of Specific Waves of Fetal and Adult B-1 and B-2 Development. <i>Immunity</i> , 2016, 45, 527-539.	14.3	64
10	Suppression of Normal and Malignant Kit Signaling by a Bispecific Antibody Linking Kit with CD300a. <i>Journal of Immunology</i> , 2008, 180, 6064-6069.	0.8	52
11	Are we ready to downregulate mast cells?. <i>Current Opinion in Immunology</i> , 2009, 21, 708-714.	5.5	52
12	Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. <i>Cell Stem Cell</i> , 2019, 25, 542-557.e9.	11.1	48
13	Human Mast Cells Undergo TRAIL-Induced Apoptosis. <i>Journal of Immunology</i> , 2006, 176, 2272-2278.	0.8	41
14	Fibroblast growth factor-7 partially reverses murine thymocyte progenitor aging by repression of <i>Ink4a</i> . <i>Blood</i> , 2012, 119, 5715-5721.	1.4	39
15	Genetic regulation of thymocyte progenitor aging. <i>Seminars in Immunology</i> , 2012, 24, 303-308.	5.6	20
16	Epigenetic Suppression of Transgenic T-cell Receptor Expression via Gamma-Retroviral Vector Methylation in Adoptive Cell Transfer Therapy. <i>Cancer Discovery</i> , 2020, 10, 1645-1653.	9.4	11
17	Human mast cells express intracellular TRAIL. <i>Cellular Immunology</i> , 2010, 262, 80-83.	3.0	9
18	IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System. <i>Clinical Cancer Research</i> , 2019, 25, 1000-1011.	7.0	9

#	ARTICLE	IF	CITATIONS
19	Influence of FAS on murine mast cell maturation. <i>Annals of Allergy, Asthma and Immunology</i> , 2011, 106, 239-244.	1.0	7
20	The Expansion of Thymopoiesis in Neonatal Mice Is Dependent on Expression of High Mobility Group A 2 Protein (Hmga2). <i>PLoS ONE</i> , 2015, 10, e0125414.	2.5	5
21	Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products. <i>Journal of Immunotherapy</i> , 2018, 41, 248-259.	2.4	3